Prasanthi Boddu, Venkata Lakshmi Cherakapu, Uma Devi Ponukumati



 Objective: Nateglinide (NTG) is a potent short-acting biopharmaceutical classification system class II antidiabetic medication. The primary objective of the present investigation was to prepare and evaluate solid dispersions of NTG to enhance the component solubility and immediate release (IR) profile. The secondary objective was to formulate sustained release (SR) matrix layer of NTG for prolonging its effect in the body and to decrease oscillations in plasma concentration level.

Methods: NTG (270 mg) SR layer was formulated using release retardant polymers such as Carbopol, ethyl cellulose (EC), hydroxy EC, hydroxypropyl methylcellulose (HPMC), Kollidon, and locust bean gum at concentrations of 15% and 30%. IR layer of NTG (60 mg) was formulated using drug: Polymer inclusion complexes (1:1 and 1:2) of β-cyclodextrin (CD), HP β-CD, polyvinylpyrrolidone (PVP) K-15, and PVP K-30 by physical mixing and kneading methods (KMs).

Results: Among the all the carriers tested HP β-CD at 1:2 ratio prepared by KM (I3) gave highest enhancement of dissolution rate and dissolution efficiency with acceptable f1 (10.5) and f2 (51.0) values in comparison to marketed IR tablets (Starlix-60®). The SR formulation S12 was able to show a minimum amount of drug release (15%) within 1 hr comparatively, with a complete and sustained effect on drug release.

Conclusion: Thus, HPMC K-100M at a concentration of 30% in the SR layer in combination with HP β-CD (1:2) solid dispersions in the IR layer may be used in the design of oral controlled drug delivery system for NTG.



Controlled release, Diabetes mellitus, Dissolution, Meglitinides, Solid dispersion, Solubility.

| PDF |


Harris MI, Cowie CC, Reiber G, editors. Diabetes in America. 2nd ed. Washington, DC: U.S. Government Printing Office; 1995.

Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13(12):1240-64.

DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med 1995;333:541-9.

Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98(5):443-51.

Jitendra RA, Mohan GK, Shrivastav GV, Yeole PG. Bilayer tablet formulation of metformin hydrochloride and gliclazide: A novel approach in the treatment of diabetes. Int J Pharm Res Dev 2009;1:1-11.

Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: Mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17 2 Suppl:11-5.

Kalbag JB, Walter YH, Nedelman JR, McLeod JF. Mealtime glucose regulation with nateglinide in healthy volunteers: Comparison with repaglinide and placebo. Diabetes Care 2001;24(1):73-7.

Kimmel B, Inzucchi SE. Oral agents for Type 2 diabetes: An update clinical. Diabetes 2005;23:64-76.

Kumar KK, Reddy MN, Kishore RN. Formulation and evaluation of bilayer matrix tablet of pioglitazone HCl metformin HCl USP 15 mg and 500 mg. Asia J Pharm Clin Res 2013;6:13.

Patel JS, Divya T, Patel KN, Patel KJ. A review on bilayer tablets. J Drug Dis Ther 2013;1:40-8.

Liu M, Cao W, Sun Y, He Z. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-ß-cyclodextrin. Int J Pharm 2014;477(1-2):159-66.

Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini MA, Adibkia K, et al. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm 2007;33(1):45-56.

Bailey CJ, Flatt PR. Development of antidiabetic drugs. In: Iaonnides C, Flatt PR, editors. Drugs, Diet and Disease, Mechanistic Approaches to Diabetes. Vol. 2. London: Ellis Horwood; 1995. p. 226-79.

Dey NS, Majumdar S, Rao ME. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008;7(3):1067.

Nadia S, Riaz U, Naz HH, Kumar BS. Enhancement of oral bioavailability and solid dispersion: A review. J Appl Pharm Sci 2011;1:13-20.

Reddy JR, Chetty CM. Enhancement of solubility of nateglinide by solid dispersion technique. J Pharm Pharmacol 2010;62:1330-1.

Bhania SB. Preparation and evaluation of solid dispersions of poorly soluble drug repaglinide. Asian J Biochem Pharm Res 2011;1:201-21.

Kavitha R, Sathali AA. Enhancement of solubility of repaglinide by solid dispersion technique. Int J Chem Sci 2012;1:377-90.

Modi VS, Thorat YS, Dhavale SC. Formulation and evaluation of controlled release delivery of tramadol hydrochloride. Int J Chemtech Res 2012;1:669-75.

Mohanachandran PN, Sidhumol PG, Kiran TS. Enhancement of solubility and dissolution rate: An overview. Int J Compr Pharm 2010;1:1-10.

Xiao DY, Wan SL, Yan JT, Cheng GL, Da HG, Hai LM. Dissolution rate enhancement of repaglinide by solid dispersion. Trop J Pharm Res 2016;15:1123-8.

Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Technol Prod Manuf 1984;5:1-9.

Reynolds TD, Gehrke SH, Hussain AS. Polymer erosion and drug release characterization of hydroxy propyl methyl cellulose matrices. J Pharm Sci 1998;87:1115-23.

Baveja SK, Hassan AU, Singh A. Zero-order release of pseudoephedrine hydrochloride from matrix tablets. Indian J Pharm Sci 1989;51:248-51.

Hemanth KG, Jaganathan K, Kumar RS, Perumal P. Formulation and in vitro evaluation of bilayer floating tablets of metformin hydrochloride and sitagliptin phosphate. Int J Appl Pharm 2012;2:64-81.

Amit K, Ramendeep G, Peeyush S, Dinesh P, Anil B. Extended release system of hypoglycemic agent containing solid dispersions: Strategies and mechanisms. Int J Med Health Biomed Bioeng Pharm Eng 2014;8:162-6.

Marques HM, Hadgraft J, Kellaway IW. Studies of cyclodextrin

inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm 1990;63:259-66.

US Pharmacopeia. United States of Pharmacopoeia 34: National Formulary 29 (USP34-NF29). Vol. 3. Washington, DC: US Pharmacopeia; 2011. p. 3611-4.

Indian Pharmacopoeia. Ministry of Health and Family Welfare. World wide Book Serivce. 7th ed., Vol. 3. New Delhi, India: The Controller of Publication; 2014.

Sonar SG, Jain DK, More DM. Preparation and in vitro evaluation of bilayer and floating-bioadhesive tablets of rosiglitazone maleate. Asian J Pharm Sci 2007;2:161-9.

Peppas NA, Sahlin JJ. A simple equation for the description of solute release III. Coupling of diffusion and relaxation. In J Pharm 1989;57:169-72.

EMEA. Committee for Proprietary Products (CPMP). Note for Guidance on Quality of Modified Release Products: A Oral Dosage Forms. London, UK: EMEA. Available from: http://www.ema.europa. eu/pdfs/human/qwp/060496en.pdf. [Last accessed on 2009 Jun 12].

Vinod M, Jitendra N, Komal P, Rahul C, Gokul K. Enhancement of solubility with formulation and in-vitro evaluation of oral nateglinide compacts by liquisolid technique. Adv Diabetes Metab 2013;1:57-64.

Vaghani SS, Patel MM, Satish CS, Patel KM, Jivani NP. Synthesis and characterization of carboxymethyl chitosan hydrogel: Application as pH-sensitive delivery for nateglinide. Curr Drug Deliv 2012;9(4):628-36.

Nicklasson M, Brodin A. The relationship between dissolution rate and solubilities in the water-ethanol binary solvent system. Int J Pharm 1984;8:149-56.

About this article




Controlled release, Diabetes mellitus, Dissolution, Meglitinides, Solid dispersion, Solubility.





Additional Links

Manuscript Submission


Asian Journal of Pharmaceutical and Clinical Research
Vol 10 Issue 11 November 2017 Page: 231-238

Print ISSN


Online ISSN


Authors & Affiliations

Prasanthi Boddu
Department of Pharmaceutical Technology, Vignan Institute of Pharmaceutical Technology, Visakhapatnam - 530 049, Andhra Pradesh, India.

Venkata Lakshmi Cherakapu
Department of Pharmaceutical Technology, Viswanadha institute of Pharmaceutical Sciences, Visakhapatnam - 530 017, Andhra Pradesh, India.

Uma Devi Ponukumati
Department of Pharmaceutical Technology, Viswanadha institute of Pharmaceutical Sciences, Visakhapatnam - 530 017, Andhra Pradesh, India.

Article Tools

Email this article (Login required)
Email the author (Login required)


  • There are currently no refbacks.